Clinical Trial

AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's Disease

Study acronym: PROSPER
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2024 (before its estimated October 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicentre prospective international observational study. This study aims to introduce a novel multidimensional approach to precision imaging, enabling the identification and stratification of high-risk patients who can potentially benefit from early treatments to halt the progression of Crohn's disease (CD). The investigators will develop a novel endoscopic assessment system using endoscopic enhanced imaging (EEI) to evaluate early post-surgical changes and predict post-operative CD recurrence (POCr). By integrating with immune marker profiling, clinical data, and AI assessment of EEI and histology, the investigators further plan to improve risk stratification and reduce interobserver variability.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06505304
Lead Sponsor University College Cork
Collaborators: The Leona M. and Harry B. Helmsley Charitable Trust
Conditions Crohn Disease
Enrollment 225 participants
Start Date 2024-05-01
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-18